ADVERTISEMENT
First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC
07/02/2020
Zev Wainberg, MD, UCLA, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC), which were presented at the virtual 2020 ESMO World Congress on Gastrointestinal Cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement